title: Antinociceptive activity of astragaloside IV in the animal model of chronic constriction injury.
abstract: To investigate the applicability of astragaloside IV (AG) for the treatment of refractory neuropathic pain, we systemically evaluated the antinociceptive activity of AG in the animal model of chronic constriction injury. We studied behaviors, electrophysiology, and biochemistry from day 2 to day 23 after the surgery. We found that when administered intraperitoneally at the dose of 60 mg/kg, AG caused significant inhibition of allodynia and hyperalgesia induced by mechanic and thermal stimuli as well as downregulation of the expressions of a series of proteins involved in mediating neuropathic pain in the dorsal root ganglia, such as P2X purinoceptor 3, glial cell-derived neurotrophic factor, glial cell-derived neurotrophic factor family receptor α1, and transient receptor potential cation channel subtypes A1 and V1. Further investigation showed that AG restored the nerve conduction velocity and the histological structure of the damaged sciatic nerve on day 23 after the surgery. Moreover, results from immunoelectron microscope showed that glial cell-derived neurotrophic factor family receptor α1 induced by AG could form a circular band in the myelin debris between the injured axons and Schwann cells, contributing toward restoration of the damaged nerve. In conclusion, in our animal model, AG effectively inhibited the neuropathic pain induced by chronic constriction injury.
authors.affiliation: aDepartments of Orthopaedic Surgery bPharmacy cUltrasonography, General Hospital of Shen-yang Military Area Command, Shenyang dDepartment of Orthopaedic Surgery, Changzheng Hospital eDepartment of Pharmacology, The Second Military Medical University, Shanghai, People's Republic of China.
authors.forename: Guo-Bing
authors.initials: GB
authors.lastname: Shi
authors.forename: Rong
authors.initials: R
authors.lastname: Fan
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Chen
authors.initials: C
authors.lastname: Yang
authors.forename: Qi
authors.initials: Q
authors.lastname: Wang
authors.forename: Juan
authors.initials: J
authors.lastname: Song
authors.forename: Yue
authors.initials: Y
authors.lastname: Gao
authors.forename: Ming-Xiao
authors.initials: MX
authors.lastname: Hou
authors.forename: Yu-Feng
authors.initials: YF
authors.lastname: Chen
authors.forename: Tong-Chao
authors.initials: TC
authors.lastname: Wang
authors.forename: Guo-Jun
authors.initials: GJ
authors.lastname: Cai
mesh_terms: D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D059350:Chronic Pain / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D003251:Constriction, Pathologic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D004195:Disease Models, Animal; D005727:Ganglia, Spinal / Q000187:drug effects / Q000503:physiopathology / Q000648:ultrastructure; D006358:Hot Temperature; D006930:Hyperalgesia / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D008297:Male; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D009336:Necrosis / Q000188:drug therapy / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D009431:Neural Conduction / Q000187:drug effects / Q000502:physiology; D009437:Neuralgia / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D017207:Rats, Sprague-Dawley; D012503:Saponins / Q000494:pharmacology*; D012584:Sciatic Nerve / Q000187:drug effects / Q000293:injuries* / Q000503:physiopathology / Q000648:ultrastructure; D014110:Touch; D014315:Triterpenes / Q000494:pharmacology*
chemical_list: D000700:Analgesics; D012503:Saponins; D014315:Triterpenes; C052064:astragaloside A